Taysha Gene Therapies Price to Free Cash Flow Ratio 2020-2026 | TSHA
Historical price to free cash flow ratio values for Taysha Gene Therapies (TSHA) since 2020.
| Taysha Gene Therapies Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-05-11 | 6.82 | 81.97 | |
| 2026-03-31 | 4.47 | $0.08 | 53.73 |
| 2025-12-31 | 5.50 | 0 | 0.00 |
| 2025-09-30 | 3.27 | $-0.28 | 0.00 |
| 2025-06-30 | 2.31 | $-0.29 | 0.00 |
| 2025-03-31 | 1.39 | $-0.32 | 0.00 |
| 2024-12-31 | 1.73 | $-0.33 | 0.00 |
| 2024-09-30 | 2.01 | $-0.42 | 0.00 |
| 2024-06-30 | 2.24 | $-0.17 | 0.00 |
| 2024-03-31 | 2.87 | $-0.37 | 0.00 |
| 2023-12-31 | 1.77 | $-0.66 | 0.00 |
| 2023-09-30 | 3.16 | $0.00 | 0.00 |
| 2023-06-30 | 0.66 | $-0.89 | 0.00 |
| 2023-03-31 | 0.80 | $-1.57 | 0.00 |
| 2022-12-31 | 2.26 | $-2.48 | 0.00 |
| 2022-09-30 | 1.93 | $-4.28 | 0.00 |
| 2022-06-30 | 3.72 | $-4.48 | 0.00 |
| 2022-03-31 | 6.52 | $-4.20 | 0.00 |
| 2021-12-31 | 11.65 | $-3.52 | 0.00 |
| 2021-09-30 | 18.62 | $-3.02 | 0.00 |
| 2021-06-30 | 21.20 | $-3.04 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |